+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Engineered T Cells Market - Global Forecast 2026-2032- Product Image
Engineered T Cells Market - Global Forecast 2026-2032- Product Image
Sale

Engineered T Cells Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989700
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Engineered T Cells Market is projected to reach USD 26.29 Billion in 2026. It is expected to continue growing at a CAGR of 8.06%, reaching USD 41.99 Billion by 2032.

Engineered T cells are redefining advanced therapy development by combining immunology, genetic engineering, cell processing, and precision oncology. The field includes chimeric antigen receptor T-cell therapy, T-cell receptor therapy, tumor-infiltrating lymphocyte approaches, gene-edited T cells, and emerging allogeneic cell therapy platforms designed to improve potency, persistence, safety, and scalability.

Commercial and clinical momentum is supported by verified regulatory approvals in hematologic malignancies, expanding clinical trial activity across solid tumors, and sustained investment in manufacturing automation, viral and non-viral gene delivery, and analytical quality control. For industry leaders, engineered T cells have moved beyond a specialized oncology niche into a strategic biopharmaceutical platform with implications for cancer care, autoimmune disease, transplant medicine, and rare immune disorders.

Transformative Shifts in Engineered T Cells

The engineered T cells landscape is shifting from first-generation autologous CAR-T programs toward broader, more industrialized therapeutic models. Key changes include the expansion from CD19- and BCMA-directed therapies into multi-antigen targeting, armored T cells, logic-gated constructs, and TCR-T therapies aimed at intracellular tumor antigens presented by HLA molecules.

Manufacturing is also transforming. Closed-system processing, automated cell expansion, improved cryopreservation, and decentralized manufacturing models are being adopted to reduce vein-to-vein time and improve consistency. At the same time, gene editing technologies are advancing allogeneic T-cell candidates by addressing rejection, graft-versus-host disease risk, and product uniformity, although long-term safety, durability, and immune compatibility remain central regulatory considerations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly cumulative across the engineered T cells value chain rather than confined to one workflow. In discovery, AI-supported antigen selection, neoantigen prediction, protein design, and single-cell data interpretation help prioritize targets and optimize receptor constructs. In translational research, machine learning is used to analyze tumor microenvironment signals, immune phenotypes, cytokine profiles, and resistance mechanisms.

In development and manufacturing, AI-enabled process monitoring can support batch consistency, deviation detection, potency assay interpretation, and predictive quality analytics. Clinical operations benefit from patient stratification, toxicity risk modeling, and real-world evidence analysis. These applications remain dependent on validated datasets, explainable models, regulatory-grade documentation, and human scientific oversight, making AI an accelerator of evidence generation rather than a substitute for clinical proof.

Key Regional Insights

North America remains a leading region for engineered T cells due to established FDA pathways for cell and gene therapies, major academic cancer centers, advanced contract development and manufacturing capacity, and high clinical trial density. Europe benefits from EMA advanced therapy medicinal product regulation, national reimbursement negotiations, and strong translational networks, while the European Union continues to support harmonized quality, traceability, and pharmacovigilance expectations for advanced therapy medicinal products.

Asia-Pacific is gaining scale through China’s large clinical trial base, Japan’s regenerative medicine framework, South Korea’s biomanufacturing strengths, India’s cost-sensitive innovation, and Australia’s early-phase clinical research infrastructure. Latin America, led by Brazil and Mexico, is building access through oncology centers, public research initiatives, and regulatory modernization, but affordability and manufacturing infrastructure remain constraints. The Middle East, particularly GCC markets, is investing in precision medicine and tertiary care capacity, while Africa’s opportunity depends on oncology infrastructure, cold-chain reliability, workforce development, and equitable access programs.

Key Group Insights

Within ASEAN, engineered T cells adoption is shaped by Singapore’s biomedical hub, Thailand and Malaysia’s hospital networks, and regional demand for cancer innovation balanced against affordability, referral pathways, and cryogenic logistics. The GCC is prioritizing advanced oncology services, genomic medicine, and partnerships that support compliant treatment centers, specialist training, and high-acuity care delivery.

The European Union provides one of the most structured regulatory environments for advanced therapy medicinal products, with emphasis on quality, traceability, pharmacovigilance, and post-authorization safety monitoring. BRICS countries collectively represent a major development frontier because China, India, Brazil, Russia, and South Africa combine large patient populations with expanding biotechnology capabilities and uneven access infrastructure. G7 countries anchor much of the innovation, reimbursement evidence, and manufacturing standard setting, while NATO-aligned countries benefit from resilient supply-chain coordination, advanced biomedical infrastructure, and cross-border clinical research collaboration.

Key Country Insights

The United States leads through FDA-approved CAR-T and T-cell immunotherapy products, extensive academic-industry collaboration, specialized treatment centers, and advanced manufacturing capacity. Canada supports adoption through cancer centers, health technology assessment processes, and regulatory alignment with international standards, while Mexico is developing capabilities through oncology modernization and cross-border healthcare linkages. Brazil is the most visible Latin American country for cell therapy development, supported by public research institutions, hospital-based innovation, and a large oncology burden.

In Europe, the United Kingdom has strong clinical translation through national health system infrastructure, cell therapy manufacturing networks, and academic centers; Germany, France, Italy, and Spain combine high oncology demand with advanced hospital systems, active clinical research, and reimbursement scrutiny. Russia maintains scientific expertise but faces access and supply-chain constraints. China has one of the world’s most active engineered T-cell clinical pipelines; India is advancing lower-cost CAR-T innovation and domestic manufacturing; Japan has a defined regenerative medicine pathway; Australia supports early-phase trials and translational oncology research; and South Korea combines biomanufacturing strength with precision medicine investment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize target differentiation, manufacturability, and clinical evidence that demonstrates durable benefit beyond response rate alone. Strategies should include early engagement with regulators, scalable quality systems, robust comparability plans, and integrated pharmacovigilance for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, insertional risk, and long-term follow-up.

Commercial success will depend on shortening vein-to-vein time, strengthening referral networks, improving patient identification, and building value-based evidence for payers. Organizations should invest in AI-enabled analytics only when datasets are validated, auditable, and clinically interpretable. Partnerships with hospitals, contract manufacturers, academic centers, and regional health authorities can accelerate access while reducing operational risk in complex cell therapy ecosystems.

Research Methodology

This executive summary is based on verified secondary research from regulatory agencies, clinical trial registries, peer-reviewed biomedical literature, healthcare policy documents, and publicly available evidence on approved cell and gene therapies. Sources considered include FDA, EMA, national regulatory authorities, ClinicalTrials.gov, EU Clinical Trials Register, WHO resources, and established scientific journals.

The analysis triangulates therapeutic approvals, trial activity, manufacturing trends, regional infrastructure, reimbursement dynamics, and technology adoption. Qualitative assessment was applied to market drivers, barriers, regional readiness, and competitive positioning. No unverified market-size figures, market share estimates, or speculative forecasts are used; insights are framed around documented regulatory, clinical, operational, and technology signals.

Conclusion

Engineered T cells are advancing from individualized breakthrough therapies toward more scalable, data-driven, and globally distributed treatment platforms. The strongest opportunities are linked to therapies that combine validated biology, differentiated clinical benefit, reproducible manufacturing, and payer-relevant outcomes.

As CAR-T, TCR-T, TIL, and gene-edited allogeneic platforms evolve, the field will reward organizations that integrate scientific rigor with operational excellence. Stakeholders that align discovery, manufacturing, regulatory strategy, AI-enabled analytics, and access planning will be best positioned to lead the next phase of engineered T-cell therapy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Engineered T Cells Market, by Therapy Type
7.1. Introduction
7.2. CAR T
7.3. TCR T
8. Engineered T Cells Market, by Cell Source
8.1. Introduction
8.2. Allogeneic
8.3. Autologous
9. Engineered T Cells Market, by Phase
9.1. Introduction
9.2. Phase I
9.3. Phase Ii
9.4. Phase Iii
9.5. Preclinical
10. Engineered T Cells Market, by Application
10.1. Introduction
10.2. Autoimmune Diseases
10.2.1. Lupus
10.2.2. Rheumatoid Arthritis
10.3. Infectious Diseases
10.4. Oncology
10.4.1. Acute Lymphoblastic Leukemia
10.4.2. Non Hodgkin Lymphoma
10.4.3. Solid Tumor
10.4.3.1. Glioblastoma
10.4.3.2. Lung Cancer
11. Engineered T Cells Market, by End User
11.1. Introduction
11.2. Hospital
11.3. Research Institutes
11.4. Specialty Clinics
12. Engineered T Cells Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Engineered T Cells Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Engineered T Cells Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Adaptimmune Therapeutics plc
16.2. Adaptin Bio, Inc.
16.3. Allogene Therapeutics, Inc.
16.4. Amgen Inc.
16.5. Atara Biotherapeutics, Inc.
16.6. Autolus Therapeutics plc
16.7. bluebird bio, Inc.
16.8. Bristol-Myers Squibb Company
16.9. CARsgen Therapeutics Ltd.
16.10. Clasp Therapeutics, Inc.
16.11. CRISPR Therapeutics AG
16.12. Fate Therapeutics, Inc.
16.13. Gilead Sciences, Inc.
16.14. Immatics N.V.
16.15. Immunocore Limited
16.16. Janux Therapeutics
16.17. Legend Biotech Corporation
16.18. Lion TCR Pte Ltd.
16.19. Novartis AG
16.20. Oxford Biomedica plc
16.21. Pfizer Inc.
16.22. Sangamo Therapeutics, Inc.
16.23. Sorrento Therapeutics, Inc.
16.24. TCR² Therapeutics Inc.
List of Figures
FIGURE 1. GLOBAL ENGINEERED T CELLS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ENGINEERED T CELLS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ENGINEERED T CELLS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CAR T MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CAR T MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CAR T MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL TCR T MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL TCR T MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL TCR T MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL LUPUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LUPUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LUPUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SOLID TUMOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SOLID TUMOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SOLID TUMOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL GLIOBLASTOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL GLIOBLASTOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GLIOBLASTOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 81. EUROPE ENGINEERED T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. EUROPE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 83. EUROPE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 84. EUROPE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 85. EUROPE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 86. EUROPE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 87. EUROPE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 88. EUROPE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 89. EUROPE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. AFRICA ENGINEERED T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 110. AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 111. AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 112. AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 113. AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 114. AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 115. AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 116. AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. NATO ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. NATO ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 129. NATO ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 130. NATO ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 131. NATO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 132. NATO ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 133. NATO ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 134. NATO ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 135. NATO ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. G7 ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. G7 ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 138. G7 ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 139. G7 ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 140. G7 ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. G7 ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 142. G7 ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 143. G7 ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 144. G7 ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. BRICS ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. BRICS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 147. BRICS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 148. BRICS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 149. BRICS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. BRICS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 151. BRICS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 152. BRICS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 153. BRICS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. ASEAN ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. ASEAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 165. ASEAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 166. ASEAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 167. ASEAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 168. ASEAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 169. ASEAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 170. ASEAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 171. ASEAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. GCC ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. GCC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 174. GCC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 175. GCC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 176. GCC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 177. GCC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 178. GCC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 179. GCC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 180. GCC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 182. CHINA ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. CHINA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 184. CHINA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 185. CHINA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 186. CHINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. CHINA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 188. CHINA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 189. CHINA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 190. CHINA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. JAPAN ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. JAPAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 202. JAPAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 203. JAPAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 204. JAPAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 205. JAPAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 206. JAPAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 207. JAPAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 208. JAPAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. INDIA ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. INDIA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 211. INDIA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 212. INDIA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 213. INDIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. INDIA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 215. INDIA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 216. INDIA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 217. INDIA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. GERMANY ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 219. GERMANY ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 220. GERMANY ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 221. GERMANY ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 222. GERMANY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 223. GERMANY ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 224. GERMANY ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 225. GERMANY ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 226. GERMANY ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 238. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 239. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 243. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 244. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 245. FRANCE ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. FRANCE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 247. FRANCE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 248. FRANCE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 249. FRANCE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 250. FRANCE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 251. FRANCE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 252. FRANCE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 253. FRANCE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 256. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 257. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 258. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 260. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 261. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. ITALY ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. ITALY ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 265. ITALY ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 266. ITALY ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 267. ITALY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. ITALY ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 269. ITALY ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 270. ITALY ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 271. ITALY ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 272. CANADA ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. CANADA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 274. CANADA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 275. CANADA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 276. CANADA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. CANADA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 278. CANADA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 279. CANADA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 280. CANADA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. BRAZIL ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 292. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 293. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 294. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 296. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 297. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 298. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. MEXICO ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. MEXICO ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 301. MEXICO ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 302. MEXICO ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 303. MEXICO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 304. MEXICO ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 305. MEXICO ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 306. MEXICO ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 307. MEXICO ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. SPAIN ENGINEERED T CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. SPAIN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 310. SPAIN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 311. SPAIN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2017-2032 (USD MILLION)
TABLE 312. SPAIN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. SPAIN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 314. SPAIN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 315. SPAIN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2017-2032 (USD MILLION)
TABLE 316. SPAIN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. GLOBAL ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 318. GLOBAL ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Adaptimmune Therapeutics plc
  • Adaptin Bio, Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics plc
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Ltd.
  • Clasp Therapeutics, Inc.
  • CRISPR Therapeutics AG
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Immatics N.V.
  • Immunocore Limited
  • Janux Therapeutics
  • Legend Biotech Corporation
  • Lion TCR Pte Ltd.
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • TCR² Therapeutics Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 26.29 Billion
Forecasted Market Value ( USD ) by 2032 $ 41.99 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Serum-free T Cell Expansion Medium Market - Global Forecast 2026-2032 - Product Image

Serum-free T Cell Expansion Medium Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Cell Therapy Biomanufacturing Market - Global Forecast 2026-2032 - Product Image

Cell Therapy Biomanufacturing Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Engineered T Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Engineered T Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From
Cell Expansion - Global Strategic Business Report - Product Image

Cell Expansion - Global Strategic Business Report

  • Report
  • 188 Pages
  • Global
From
Cell Separation Technologies - Global Strategic Business Report - Product Image

Cell Separation Technologies - Global Strategic Business Report

  • Report
  • 286 Pages
  • Global
From

About the Engineered T Cell Market

Engineered T Cells are a type of biotechnology that involves the genetic engineering of a patient's own T cells to create a personalized therapy for the treatment of cancer and other diseases. This technology is based on the idea of using the body's own immune system to fight disease. The engineered T cells are modified to recognize and attack cancer cells, while leaving healthy cells unharmed. This technology has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. Engineered T Cells are a rapidly growing field of biotechnology, with many companies developing new treatments and therapies. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in this field, developing innovative treatments and therapies for cancer and other diseases. Other companies such as Cellectis, Bluebird Bio, and Bellicum Pharmaceuticals are also making significant contributions to the field. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.